BioGeometry closes hundreds-of-millions-yuan Series A for AI-driven protein design
What's the deal? Beijing-based BioGeometry (百奥几何) has closed a strategic funding round worth hundreds of millions of yuan. The round was co-led by Shanghai Biomedical Innovation and Transformation FundDealroom has a profile for this one. Try Dealroom →, Guoke Investment, Fortune CapitalDealroom has a profile for this one. Try Dealroom →, and Xinglian Capital, with Gaorong CapitalDealroom has a profile for this one. Try Dealroom → and Index AI Industry Innovation Fund participating. The proceeds will fund continued development of GeoFlow — the company's "micro-world model" for life sciences — and advance its proprietary drug pipelines.
Founded in 2021 by AI-for-science researcher Professor Tang Jian, BioGeometry uses generative AI to model molecular interactions at atomic-level precision and design entirely new proteins, antibodies, and enzymes from scratch. Turing Award winner Yoshua Bengio serves as chief scientific adviser.
Why now? AI-driven drug discovery is attracting unprecedented capital and scientific attention. In May 2026, AlphabetDealroom has a profile for this one. Try Dealroom →'s Isomorphic Labs raised $2.1B — the largest single round in the field. The 2024 Nobel Prize in Chemistry went to protein structure prediction and de novo protein design. And China's innovative drug licensing deals hit $135.7B in 2025, surpassing the US to become the world's largest out-licensing market.
BioGeometry's own technology has matured rapidly. Its GeoFlow model has gone through three major upgrades since launching in 2024. The latest version, V3, applies test-time scaling techniques from large language models to protein design, generating multiple candidate molecules per target and filtering for quality. Across more than 20 targets, the company says it needs to synthesise and test fewer than 50 candidates per target to find antibodies with nanomolar-level binding — with a hit rate near 20% and lead discovery times under three weeks.
What could go wrong? AI-designed molecules still need to survive the long, expensive journey through clinical trials. Computational success in early-stage design does not guarantee real-world drug efficacy or safety. The company also faces rising global competition, particularly from well-funded Western rivals like Isomorphic Labs that can draw on vast proprietary datasets.
BioGeometry's funding amount — described only as "hundreds of millions of yuan" — may prove modest against the billions flowing into the sector globally.
The signal: BioGeometry's investor mix — combining a Shanghai biomedical fund, state-backed Guoke Investment, and tech-oriented Gaorong Capital — reflects how China's AI-for-drug-discovery ecosystem is being underwritten by a convergence of public health policy capital and private venture money. With over 20 pharma partnerships already signed and several synthetic biology pipelines reaching pilot-scale production, BioGeometry is progressing toward commercial revenue at a stage when many AI drug discovery startups remain pre-partnership, though the undisclosed round size suggests it is still modestly capitalised against global peers flush with billions.
Read more: 36kr.com
